Catecholamine use is associated with enterocyte damage in critically ill patients.
Identifieur interne : 003077 ( Main/Exploration ); précédent : 003076; suivant : 003078Catecholamine use is associated with enterocyte damage in critically ill patients.
Auteurs : Gaël Piton [Australie] ; Benoit Cypriani ; Jacques Regnard ; Cyrille Patry ; Marc Puyraveau ; Gilles CapellierSource :
- Shock (Augusta, Ga.) [ 1540-0514 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Catécholamines (effets indésirables), Catécholamines (sang), Catécholamines (usage thérapeutique), Choc septique (physiopathologie), Choc septique (sang), Entérocytes (), Entérocytes (anatomopathologie), Femelle, Humains, Hémodynamique, Intestin grêle (), Intestin grêle (anatomopathologie), Maladie grave, Mâle, Norépinéphrine (administration et posologie), Odds ratio, Pronostic, Protéines de liaison aux acides gras (sang), Soins de réanimation, Sujet âgé, Unités de soins intensifs, Vitesse du flux sanguin, Épinéphrine (administration et posologie), Études prospectives.
- MESH :
- administration et posologie : Norépinéphrine, Épinéphrine.
- anatomopathologie : Entérocytes, Intestin grêle.
- effets indésirables : Catécholamines.
- physiopathologie : Choc septique.
- sang : Catécholamines, Choc septique, Protéines de liaison aux acides gras.
- usage thérapeutique : Catécholamines.
- Adulte d'âge moyen, Entérocytes, Femelle, Humains, Hémodynamique, Intestin grêle, Maladie grave, Mâle, Odds ratio, Pronostic, Soins de réanimation, Sujet âgé, Unités de soins intensifs, Vitesse du flux sanguin, Études prospectives.
English descriptors
- KwdEn :
- Aged, Blood Flow Velocity, Catecholamines (adverse effects), Catecholamines (blood), Catecholamines (therapeutic use), Critical Care, Critical Illness, Enterocytes (drug effects), Enterocytes (pathology), Epinephrine (administration & dosage), Fatty Acid-Binding Proteins (blood), Female, Hemodynamics, Humans, Intensive Care Units, Intestine, Small (drug effects), Intestine, Small (pathology), Male, Middle Aged, Norepinephrine (administration & dosage), Odds Ratio, Prognosis, Prospective Studies, Shock, Septic (blood), Shock, Septic (physiopathology).
- MESH :
- chemical , administration & dosage : Epinephrine, Norepinephrine.
- chemical , adverse effects : Catecholamines.
- chemical , blood : Catecholamines, Fatty Acid-Binding Proteins.
- chemical , therapeutic use : Catecholamines.
- blood : Shock, Septic.
- drug effects : Enterocytes, Intestine, Small.
- pathology : Enterocytes, Intestine, Small.
- physiopathology : Shock, Septic.
- Aged, Blood Flow Velocity, Critical Care, Critical Illness, Female, Hemodynamics, Humans, Intensive Care Units, Male, Middle Aged, Odds Ratio, Prognosis, Prospective Studies.
Abstract
Small bowel damage is frequent but underdiagnosed among critically ill patients with shock. High catecholamine doses may have a deleterious effect on mesenteric blood flow. Plasma intestinal fatty acid-binding protein (I-FABP) concentration is a marker of enterocyte damage, whereas plasma citrulline concentration is a marker of functional enterocyte mass. We hypothesized that high doses of catecholamines in critically ill patients may be associated with enterocyte damage. This study aimed to determine the link between catecholamine use and dose with enterocyte damage. This is a prospective observational study performed in a large regional university teaching hospital. Critically ill patients requiring epinephrine and/or norepinephrine at admission to a medical intensive care unit (ICU) were included, as well as controls not receiving catecholamines. We evaluated at admission plasma I-FABP and citrulline concentrations, abdominal perfusion pressure (APP), and variables relating to prognosis and treatment. Patients were categorized according to the quartiles of catecholamine dose at ICU admission. Sixty critically ill patients receiving catecholamines and 27 not receiving catecholamines were included. Plasma I-FABP was higher among patients receiving catecholamine than in controls. Among patients receiving catecholamines, a dose of 0.48 γ kg min or more at ICU admission was associated with a higher I-FABP concentration. A Sepsis-related Organ Failure Assessment score higher than 11 and plasma I-FABP more than 524 pg mL at ICU admission were independently associated with 28-day mortality (odds ratio, 4.0 [1.24-12.95] and odds ratio, 4.90 [1.44-16.6], respectively). Catecholamine use is associated with I-FABP elevation in critically ill patients. Critically ill patients receiving more than 0.48 γ kg min of epinephrine and/or norepinephrine at ICU admission have high I-FABP concentrations. This suggests that enterocyte damage reflects the severity of shock, and an adverse effect of catecholamines per se is possible.
DOI: 10.1097/SHK.0000000000000327
PubMed: 25565647
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002D79
- to stream PubMed, to step Curation: 002D04
- to stream PubMed, to step Checkpoint: 002D04
- to stream Ncbi, to step Merge: 002147
- to stream Ncbi, to step Curation: 002147
- to stream Ncbi, to step Checkpoint: 002147
- to stream Main, to step Merge: 003078
- to stream Main, to step Curation: 003077
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Catecholamine use is associated with enterocyte damage in critically ill patients.</title><author><name sortKey="Piton, Gael" sort="Piton, Gael" uniqKey="Piton G" first="Gaël" last="Piton">Gaël Piton</name><affiliation wicri:level="1"><nlm:affiliation>*Medical Intensive Care Unit, University Hospital, Besançon, France, †Research Unit EA 3920 and SFR FED 4234, University of Franche Comté, Besançon, France, ‡Clinical Chemistry Unit, §Physiology Department, ∥Clinical Methodology Center, University Hospital, Besançon, France; and ¶Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Clayton, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>*Medical Intensive Care Unit, University Hospital, Besançon, France, †Research Unit EA 3920 and SFR FED 4234, University of Franche Comté, Besançon, France, ‡Clinical Chemistry Unit, §Physiology Department, ∥Clinical Methodology Center, University Hospital, Besançon, France; and ¶Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Clayton</wicri:regionArea><wicri:noRegion>Clayton</wicri:noRegion></affiliation></author><author><name sortKey="Cypriani, Benoit" sort="Cypriani, Benoit" uniqKey="Cypriani B" first="Benoit" last="Cypriani">Benoit Cypriani</name></author><author><name sortKey="Regnard, Jacques" sort="Regnard, Jacques" uniqKey="Regnard J" first="Jacques" last="Regnard">Jacques Regnard</name></author><author><name sortKey="Patry, Cyrille" sort="Patry, Cyrille" uniqKey="Patry C" first="Cyrille" last="Patry">Cyrille Patry</name></author><author><name sortKey="Puyraveau, Marc" sort="Puyraveau, Marc" uniqKey="Puyraveau M" first="Marc" last="Puyraveau">Marc Puyraveau</name></author><author><name sortKey="Capellier, Gilles" sort="Capellier, Gilles" uniqKey="Capellier G" first="Gilles" last="Capellier">Gilles Capellier</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25565647</idno><idno type="pmid">25565647</idno><idno type="doi">10.1097/SHK.0000000000000327</idno><idno type="wicri:Area/PubMed/Corpus">002D79</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D79</idno><idno type="wicri:Area/PubMed/Curation">002D04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002D04</idno><idno type="wicri:Area/PubMed/Checkpoint">002D04</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002D04</idno><idno type="wicri:Area/Ncbi/Merge">002147</idno><idno type="wicri:Area/Ncbi/Curation">002147</idno><idno type="wicri:Area/Ncbi/Checkpoint">002147</idno><idno type="wicri:Area/Main/Merge">003078</idno><idno type="wicri:Area/Main/Curation">003077</idno><idno type="wicri:Area/Main/Exploration">003077</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Catecholamine use is associated with enterocyte damage in critically ill patients.</title><author><name sortKey="Piton, Gael" sort="Piton, Gael" uniqKey="Piton G" first="Gaël" last="Piton">Gaël Piton</name><affiliation wicri:level="1"><nlm:affiliation>*Medical Intensive Care Unit, University Hospital, Besançon, France, †Research Unit EA 3920 and SFR FED 4234, University of Franche Comté, Besançon, France, ‡Clinical Chemistry Unit, §Physiology Department, ∥Clinical Methodology Center, University Hospital, Besançon, France; and ¶Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Clayton, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>*Medical Intensive Care Unit, University Hospital, Besançon, France, †Research Unit EA 3920 and SFR FED 4234, University of Franche Comté, Besançon, France, ‡Clinical Chemistry Unit, §Physiology Department, ∥Clinical Methodology Center, University Hospital, Besançon, France; and ¶Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Clayton</wicri:regionArea><wicri:noRegion>Clayton</wicri:noRegion></affiliation></author><author><name sortKey="Cypriani, Benoit" sort="Cypriani, Benoit" uniqKey="Cypriani B" first="Benoit" last="Cypriani">Benoit Cypriani</name></author><author><name sortKey="Regnard, Jacques" sort="Regnard, Jacques" uniqKey="Regnard J" first="Jacques" last="Regnard">Jacques Regnard</name></author><author><name sortKey="Patry, Cyrille" sort="Patry, Cyrille" uniqKey="Patry C" first="Cyrille" last="Patry">Cyrille Patry</name></author><author><name sortKey="Puyraveau, Marc" sort="Puyraveau, Marc" uniqKey="Puyraveau M" first="Marc" last="Puyraveau">Marc Puyraveau</name></author><author><name sortKey="Capellier, Gilles" sort="Capellier, Gilles" uniqKey="Capellier G" first="Gilles" last="Capellier">Gilles Capellier</name></author></analytic><series><title level="j">Shock (Augusta, Ga.)</title><idno type="eISSN">1540-0514</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Blood Flow Velocity</term><term>Catecholamines (adverse effects)</term><term>Catecholamines (blood)</term><term>Catecholamines (therapeutic use)</term><term>Critical Care</term><term>Critical Illness</term><term>Enterocytes (drug effects)</term><term>Enterocytes (pathology)</term><term>Epinephrine (administration & dosage)</term><term>Fatty Acid-Binding Proteins (blood)</term><term>Female</term><term>Hemodynamics</term><term>Humans</term><term>Intensive Care Units</term><term>Intestine, Small (drug effects)</term><term>Intestine, Small (pathology)</term><term>Male</term><term>Middle Aged</term><term>Norepinephrine (administration & dosage)</term><term>Odds Ratio</term><term>Prognosis</term><term>Prospective Studies</term><term>Shock, Septic (blood)</term><term>Shock, Septic (physiopathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Catécholamines (effets indésirables)</term><term>Catécholamines (sang)</term><term>Catécholamines (usage thérapeutique)</term><term>Choc septique (physiopathologie)</term><term>Choc septique (sang)</term><term>Entérocytes ()</term><term>Entérocytes (anatomopathologie)</term><term>Femelle</term><term>Humains</term><term>Hémodynamique</term><term>Intestin grêle ()</term><term>Intestin grêle (anatomopathologie)</term><term>Maladie grave</term><term>Mâle</term><term>Norépinéphrine (administration et posologie)</term><term>Odds ratio</term><term>Pronostic</term><term>Protéines de liaison aux acides gras (sang)</term><term>Soins de réanimation</term><term>Sujet âgé</term><term>Unités de soins intensifs</term><term>Vitesse du flux sanguin</term><term>Épinéphrine (administration et posologie)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Epinephrine</term><term>Norepinephrine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Catecholamines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Catecholamines</term><term>Fatty Acid-Binding Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Catecholamines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Norépinéphrine</term><term>Épinéphrine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Entérocytes</term><term>Intestin grêle</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Shock, Septic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Enterocytes</term><term>Intestine, Small</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Catécholamines</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Enterocytes</term><term>Intestine, Small</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Choc septique</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Shock, Septic</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Catécholamines</term><term>Choc septique</term><term>Protéines de liaison aux acides gras</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Catécholamines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Blood Flow Velocity</term><term>Critical Care</term><term>Critical Illness</term><term>Female</term><term>Hemodynamics</term><term>Humans</term><term>Intensive Care Units</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Prognosis</term><term>Prospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Entérocytes</term><term>Femelle</term><term>Humains</term><term>Hémodynamique</term><term>Intestin grêle</term><term>Maladie grave</term><term>Mâle</term><term>Odds ratio</term><term>Pronostic</term><term>Soins de réanimation</term><term>Sujet âgé</term><term>Unités de soins intensifs</term><term>Vitesse du flux sanguin</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Small bowel damage is frequent but underdiagnosed among critically ill patients with shock. High catecholamine doses may have a deleterious effect on mesenteric blood flow. Plasma intestinal fatty acid-binding protein (I-FABP) concentration is a marker of enterocyte damage, whereas plasma citrulline concentration is a marker of functional enterocyte mass. We hypothesized that high doses of catecholamines in critically ill patients may be associated with enterocyte damage. This study aimed to determine the link between catecholamine use and dose with enterocyte damage. This is a prospective observational study performed in a large regional university teaching hospital. Critically ill patients requiring epinephrine and/or norepinephrine at admission to a medical intensive care unit (ICU) were included, as well as controls not receiving catecholamines. We evaluated at admission plasma I-FABP and citrulline concentrations, abdominal perfusion pressure (APP), and variables relating to prognosis and treatment. Patients were categorized according to the quartiles of catecholamine dose at ICU admission. Sixty critically ill patients receiving catecholamines and 27 not receiving catecholamines were included. Plasma I-FABP was higher among patients receiving catecholamine than in controls. Among patients receiving catecholamines, a dose of 0.48 γ kg min or more at ICU admission was associated with a higher I-FABP concentration. A Sepsis-related Organ Failure Assessment score higher than 11 and plasma I-FABP more than 524 pg mL at ICU admission were independently associated with 28-day mortality (odds ratio, 4.0 [1.24-12.95] and odds ratio, 4.90 [1.44-16.6], respectively). Catecholamine use is associated with I-FABP elevation in critically ill patients. Critically ill patients receiving more than 0.48 γ kg min of epinephrine and/or norepinephrine at ICU admission have high I-FABP concentrations. This suggests that enterocyte damage reflects the severity of shock, and an adverse effect of catecholamines per se is possible.</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Capellier, Gilles" sort="Capellier, Gilles" uniqKey="Capellier G" first="Gilles" last="Capellier">Gilles Capellier</name><name sortKey="Cypriani, Benoit" sort="Cypriani, Benoit" uniqKey="Cypriani B" first="Benoit" last="Cypriani">Benoit Cypriani</name><name sortKey="Patry, Cyrille" sort="Patry, Cyrille" uniqKey="Patry C" first="Cyrille" last="Patry">Cyrille Patry</name><name sortKey="Puyraveau, Marc" sort="Puyraveau, Marc" uniqKey="Puyraveau M" first="Marc" last="Puyraveau">Marc Puyraveau</name><name sortKey="Regnard, Jacques" sort="Regnard, Jacques" uniqKey="Regnard J" first="Jacques" last="Regnard">Jacques Regnard</name></noCountry><country name="Australie"><noRegion><name sortKey="Piton, Gael" sort="Piton, Gael" uniqKey="Piton G" first="Gaël" last="Piton">Gaël Piton</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003077 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003077 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25565647
|texte= Catecholamine use is associated with enterocyte damage in critically ill patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25565647" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |